A meta-analysis was conducted to evaluate the association between KRAS mutations and overall survival (OS) in NSCLC patients receiving first-line immune checkpoint inhibitor (ICI) monotherapy. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.